









Cheung Wilson Wai-Shun - Insider Stock Trading - OpenInsider











Sector

All Sectors

Group by Sector


Aerospace
Agriculture
Automobile
Building
Business Services
Chemical
Electrical
Energy
Fashion
Financial
Food & Beverage
Fund
Healthcare
Household
Insurance
Machinery
Media
Metals
Mining
Other
Personal Services
Real Estate
Retail
Technology
Telecom
Transportation
Utility




Industry

All Industries

Group by Industry






Insiders
Filings


All
Purchases
Sales

CIK: 1291656 - Address: 950 Tower Lane, Suite 900, Foster City, CA 94404 27 results 

						Links
						


SECYahooGoogleFinvizTradingViewStockChartsStockTwitsDownload CSV 













TC
Stat
Stk
Ins
Fil
+d
+w
+m
+q
+h
+y
avg


P%ret111-4-15-6-8-26956P%wins0000010017S%ret2112-1-3-1-5-28-62-17S%wins75675075928874 




Filing Date
T Date
Ticker
IssuerInc Sector
IndIndustry
Owner
oSt
Rel
Title
T
TVal
Price
L
Qty
oc
Own
H
r2y
r1y
r6m
r3m
r6w
r3w
r7d
r3d
f1d
f1w
f1m
f3m
f6m
f1y



6/14/17 16:556/12/17SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,M.d00.000412D
6/14/17 16:556/12/17SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,S.d-43510.750-41-962D
3/17/17 16:443/15/17SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,M.d00.00232D95-6-6-5-100411
10/27/16 13:0010/26/16SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,M.d7395.4821350D2730-25-5-4-402-8-1045-2
10/27/16 13:0010/25/16SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,S.dm-1,50010.002-150-1000D2730-25-5-4-402-8-1045-2
10/19/16 16:4910/17/16SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,M.d65.9731715D2629-24-5-6-8-4-2-1166-2
10/19/16 16:4910/17/16SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,S.d-1510.003-1-915D2629-24-5-6-8-4-2-1166-2
8/29/16 17:128/29/16SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,S-1910.356-2-1116D54356-20-21-121-1-3-1-2-5
8/16/16 14:438/12/16SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,M.d00.0054117D853122-14-19542-1-4-6-8-8
8/16/16 14:438/16/16SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,S.d-8310.625-8-3117D853122-14-19542-1-4-6-8-8
11/10/15 17:0111/10/15SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,S-749.512-8-1000D834-160198513-6-8-1537-6
8/17/15 12:368/13/15SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,M.d00.004138D52414-13-25-14-1122-1-67731
3/16/15 11:263/12/15SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,S-719.073-8-1000D82871701713992137-710
8/18/14 14:538/14/14SCLNSciclone Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsCheung Wilson Wai-ShunCAOCFO,SVP,M.d00.001138D2613212512192094519442739
11/10/08 16:3111/10/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOP11.2601New1D-73-70-73-64-37-20-18-4-15-6-8-2695
5/2/08 15:525/1/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOM.d372.241170D14221-171-2-3-3521-16-72-83
5/2/08 15:525/1/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOS.d-855.111-17-1000D14221-171-2-3-3521-16-72-83
4/29/08 17:094/28/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOM.d82.24030D1321-19-75-1-1-103-3-14-74-80
4/29/08 17:094/28/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOS.d-175.000-3-1000D1321-19-75-1-1-103-3-14-74-80
4/8/08 13:204/7/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOM.d222.240100D178-22-16-2937-2-6-4-16-65-83
4/8/08 13:204/7/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOS.d-505.000-10-1000D178-22-16-2937-2-6-4-16-65-83
3/28/08 12:033/27/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOM.d202.24190D44-5-18-17-9-45-1-1-13-5-56-84
3/28/08 12:033/27/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOS.d-455.011-9-1000D44-5-18-17-9-45-1-1-13-5-56-84
3/26/08 11:593/24/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOM.d22.24110D51-5-15-6-11-50-10-11-3-55-85
3/26/08 11:593/24/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOS.d-55.001-1-1000D51-5-15-6-11-50-10-11-3-55-85
3/10/08 13:333/6/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOM.d222.241100D5633200-4-15-1-5-6-3-4-29-84
3/10/08 13:333/6/08AXTIAxt IncDETechSemicnSemiconductors & Related DeviCheung Wilson Wai-ShunCAOCFOS.d-505.031-10-1000D5633200-4-15-1-5-6-3-4-29-84



DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing



S - SaleSale of securities on an exchange or to another person

S - Sale+OESale of securities on an exchange or to another person (after option exercise)

F - TaxPayment of exercise price or tax liability using portion of securities received from the company

P - PurchasePurchase of securities on an exchange or from another person


Return to top
Contact
Copyright © 2017 OpenInsider.com. All rights reserved.




﻿






























Wilson Wai-Shun Cheung Sells 40,500 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock - Chaffey Breeze













































 
















 



  
 
 
























Daily Ratings & News for SciClone Pharmaceuticals Inc.

        
	Complete the form below to receive the latest headlines and analysts' recommendationsfor SciClone Pharmaceuticals Inc. with our free daily email newsletter:










Follow @chaffeybreeze












Recent Posts

Hawaiian Holdings’ (HA) Underweight Rating Reaffirmed at Morgan Stanley
Gilead Sciences, Inc. (GILD) Upgraded at BidaskClub
G-III Apparel Group, LTD. (GIII) Downgraded to Sell at BidaskClub
O’Reilly Automotive, Inc. (ORLY) Position Maintained by Capital Impact Advisors LLC
Analysts Expect Danaher Corporation (NYSE:DHR) Will Post Quarterly Sales of $4.42 Billion
Analysts Set Varonis Systems, Inc. (VRNS) Target Price at $39.00
Critical Contrast: Platform Specialty Products Corporation (PAH) & TerraVia Holdings (NASDAQ:TVIA)
UTi Worldwide (NASDAQ:UTIW) & Air Transport Services Group (ATSG) Head to Head Survey
Ultralife Corporation (NASDAQ:ULBI) versus Arotech Corporation (ARTX) Head to Head Contrast
Contrasting Gentiva Health Services (GTIV) & Addus HomeCare Corporation (ADUS)
Head to Head Review: GasLog LP. (GLOG) vs. Golar LNG Partners (GMLP)
Calumet Specialty Products Partners, L.P. (CLMT) Rating Increased to Strong-Buy at Zacks Investment Research
Juno Therapeutics, Inc. (NASDAQ:JUNO) Rating Increased to Buy at Zacks Investment Research
Eastman Chemical Company (NYSE:EMN) Expected to Post Quarterly Sales of $2.37 Billion
Winnebago Industries, Inc. (NYSE:WGO) Earns “Market Perform” Rating from BMO Capital Markets
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Boosted by Advantus Capital Management Inc
Morgan Stanley Has $54.02 Million Stake in BWX Technologies, Inc. (NYSE:BWXT)
Analyzing Allot Communications (ALLT) and Zayo Group Holdings (ZAYO)
6,645 Shares in Parsley Energy, Inc. (PE) Acquired by Two Sigma Securities LLC
Weiss Multi Strategy Advisers LLC Takes Position in Puma Biotechnology Inc (NYSE:PBYI)







Wilson Wai-Shun Cheung Sells 40,500 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock


					Posted by Charlotte Bryant on Jul 15th, 2017 // No Comments




SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) CFO Wilson Wai-Shun Cheung sold 40,500 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $10.75, for a total transaction of $435,375.00. Following the completion of the transaction, the chief financial officer now owns 14,372 shares of the company’s stock, valued at $154,499. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 
SciClone Pharmaceuticals, Inc. (SCLN) traded up 0.23% during mid-day trading on Friday, hitting $10.95. 871,052 shares of the stock were exchanged. SciClone Pharmaceuticals, Inc. has a 12-month low of $8.55 and a 12-month high of $13.73. The firm has a 50-day moving average price of $10.18 and a 200-day moving average price of $10.02. The stock has a market capitalization of $566.47 million, a P/E ratio of 15.40 and a beta of 1.71. 


 Get SciClone Pharmaceuticals Inc. alerts:



WARNING: “Wilson Wai-Shun Cheung Sells 40,500 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock” was first  reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/07/15/wilson-wai-shun-cheung-sells-40500-shares-of-sciclone-pharmaceuticals-inc-scln-stock.html. 
Institutional investors have recently modified their holdings of the stock. Allianz Asset Management AG raised its position in shares of  SciClone Pharmaceuticals by 25.6% in the fourth quarter. Allianz Asset Management AG now owns 103,801 shares of the specialty pharmaceutical company’s stock valued at $1,121,000 after buying an additional 21,149 shares in the last quarter.  Metropolitan Life Insurance Co. NY raised its position in shares of  SciClone Pharmaceuticals by 6.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 39,519 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 2,389 shares in the last quarter.  Guggenheim Capital LLC acquired a new position in shares of  SciClone Pharmaceuticals during the fourth quarter valued at about $1,996,000.  Russell Investments Group Ltd. acquired a new position in shares of  SciClone Pharmaceuticals during the fourth quarter valued at about $1,400,000.  Finally, GSA Capital Partners LLP raised its position in shares of  SciClone Pharmaceuticals by 14.7% in the fourth quarter. GSA Capital Partners LLP now owns 231,214 shares of the specialty pharmaceutical company’s stock valued at $2,497,000 after buying an additional 29,701 shares in the last quarter. Institutional investors and hedge funds own  71.80% of the company’s stock. 





Separately, Maxim Group  set a $14.00 price target on shares of SciClone Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 11th.
About SciClone Pharmaceuticals
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.







Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.








 






















Latest News





Leave a Reply

Click here to cancel reply.




Name  (Required) 



Mail (will not be published)  (Required) 



Website












 

 






















































































Wilson Wai-shun Cheung - Fremont, CA | Intelius



























Sign In



We found Wilson Wai-Shun Cheung in Fremont, CA


Wilson Wai-Shun Cheung

                                                                           Intelius found that Wilson Wai-shun Cheung  is  a male between 40 and 50 years old from Fremont, CA.  We have connected them to
                15 addresses,
                7 phones,
                and 9 relatives or associates.
         





Also Known As

Wilson S Cheung


Get Report Now

Age

Wilson Wai-Shun Cheung is in his 40s

Wilson Has Lived In

Fremont, CA
Walnut, CA
Hayward, CA

Wilson's Relatives

Michelle Cheung
Virginia Cheung
Karen Cheung
Philip Cheung







Wilson Wai-Shun Cheung



Zodiac SignAquarius



GenderMale



Get Report Now










Want to know more about Wilson? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Wilson, or use our people search engine to find others.
Get Background Check on Wilson Wai-Shun Cheung
Get a Criminal Check on Wilson Wai-Shun Cheung
Get a Public Record Report on Wilson Wai-Shun Cheung
Get a People Search Report on Wilson Wai-Shun Cheung


Wilson Wai-Shun Cheung's Contact Information
Known Cities Lived In
Find out where Wilson Wai-Shun Cheung has lived as well as Wilson Wai-Shun Cheung's phone numbers and email addresses.




Wilson Wai-Shun Cheung Has Lived in 2 States
California Address for Wilson Wai-Shun Cheung


44212 L***** P* 

Fremont, CA


Has Lived In

Fremont, CA
Walnut, CA


Get Full Address Report










Phone Numbers Associated with Wilson Wai-Shun Cheung

(510) ***-**** - Fremont, CA 
(510) ***-**** - Fremont, CA 
(510) ***-**** - Fremont, CA 


Get Full Phone Report



Email Addresses Associated with Wilson Wai-Shun Cheung

w**********g@***.net
w*****g@***.com
w***********g@***.net


Get Email Report




Wilson Wai-Shun Cheung's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Wilson Wai-Shun Cheung


Wilson Wai-Shun Cheung's known Social Networks And Potential Email Matches

Find all of Wilson Wai-Shun Cheung's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Wilson Cheung
Username Matches

                  WilsonCheung
                  CheungWilson
                  Wilson.Cheung
                  Cheung.Wilson
                  Wilson_Cheung
                  Cheung_Wilson
                  Wilson-Cheung
                  Cheung-Wilson
                  WCheung
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
W Cheung







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.



































SciClone Pharmaceuticals (SCLN) Receives Daily News Impact Score of 0.30 - Watch List News



















































Home
About
Staff
Privacy Policy
Contact
























Headlines
Business
US News
Health
World
Investing
Technology




















SciClone Pharmaceuticals Inc. - Get News & Ratings Daily

		Enter your email address below to get the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. with our FREE daily email newsletter:



 






Follow Watchlist News

 











Latest News



At Home Group Inc (NASDAQ:HOME) Downgraded to Sell at Zacks Investment Research					

Zacks Investment Research Upgrades KCAP Financial, Inc. (KCAP) to Hold					

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Upgraded to “Hold” at Zacks Investment Research					

Kingfisher plc (KGFHY) Rating Lowered to Sell at Zacks Investment Research					

Lion Biotechnologies, Inc. (NASDAQ:IOVA) Upgraded to “Buy” at Zacks Investment Research					

Jc Decaux Sa (NASDAQ:JCDXF) Rating Lowered to Sell at Zacks Investment Research					

Hess Midstream Partners LP (NASDAQ:HESM) Upgraded to Buy by Zacks Investment Research					

Harmonic Inc. (NASDAQ:HLIT) Lowered to Strong Sell at Zacks Investment Research					

GoPro, Inc. (GPRO) Upgraded by Vetr Inc. to Strong-Buy					

Alphabet Inc. (GOOGL) Stock Rating Lowered by Vetr Inc.					

Zacks Investment Research Upgrades Harvest Capital Credit Corporation (NASDAQ:HCAP) to Hold					

GlycoMimetics, Inc. (GLYC) Stock Rating Upgraded by Zacks Investment Research					

Zacks Investment Research Lowers Galectin Therapeutics Inc. (NASDAQ:GALT) to Hold					

NIC Inc. (EGOV) Upgraded to Buy by Zacks Investment Research					

8×8 Inc (EGHT) Raised to Buy at Zacks Investment Research					

DASAN Zhone Solutions, Inc. (DZSI) Cut to “Hold” at Zacks Investment Research					

Dicerna Pharmaceuticals, Inc. (DRNA) Rating Lowered to Sell at Zacks Investment Research					

Zacks Investment Research Downgrades IDI, Inc. (NASDAQ:COGT) to Sell					

Differential Brands Group Inc. (DFBG) Upgraded by Zacks Investment Research to “Hold”					

lululemon athletica inc. (NASDAQ:LULU) Receives New Coverage from Analysts at Needham & Company LLC					



Archives

July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
March 2016
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014




 




						SciClone Pharmaceuticals (SCLN) Receives Daily News Impact Score of 0.30					

						 July 17th, 2017  - 0 comments - Filed Under -
 by Hanz Christensen 


							Filed Under: Investing - News Sentiment Articles 






Tweet










Media coverage about SciClone Pharmaceuticals (NASDAQ:SCLN) has trended positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SciClone Pharmaceuticals earned a daily sentiment score of 0.30 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 43 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future. 
SciClone Pharmaceuticals (SCLN) traded down 0.228% during mid-day trading on Monday, hitting $10.925. 145,369 shares of the stock traded hands. The stock has a 50-day moving average of $10.18 and a 200 day moving average of $10.02. SciClone Pharmaceuticals has a 1-year low of $8.55 and a 1-year high of $13.46. The firm has a market cap of $565.17 million, a price-to-earnings ratio of 15.366 and a beta of 1.70. 
Separately, Maxim Group  restated a “hold” rating on shares of SciClone Pharmaceuticals in a research note on Thursday, June 8th.




TRADEMARK VIOLATION WARNING: This report was first  published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/sciclone-pharmaceuticals-scln-receives-daily-news-impact-score-of-0-30/1445171.html. 
In other news, CEO Friedhelm Blobel sold 40,000 shares of the business’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $9.56, for a total transaction of $382,400.00. Following the completion of the transaction, the chief executive officer now owns 104,204 shares of the company’s stock, valued at $996,190.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Wilson Wai-Shun Cheung sold 40,500 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $10.75, for a total transaction of $435,375.00. Following the transaction, the chief financial officer now directly owns 14,372 shares of the company’s stock, valued at approximately $154,499. The disclosure for this sale can be found here. In the last three months, insiders have sold 298,126 shares of company stock valued at $3,088,468. Corporate insiders own  5.16% of the company’s stock. 
About SciClone Pharmaceuticals
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.



Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.



 










Hanz Christensen 























 Comment on this Post

Click here to cancel reply.



Name (required)

Mail (will not be published) (required)

Website






Wordpress Hashcash needs javascript to work, but your browser has javascript disabled. Your comment will be placed in moderation!




Latest News




Sirius XM Making Big Investment In Pandora





Tax Reform Not Going Quite As Planned





Western Digital Files Lawsuit To Halt Toshiba Chip Business Sale





Sinclair Broadcast Group Announces Deal For Tribune Media





Starbucks Has A Hit With Its Unicorn Frappuccino











			© Watch List News, LLC 2008-2017. All rights reserved. 


Privacy Policy |
			About | Staff 
			| Contact 













































CHEUNG WILSON WAI-SHUN Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      CHEUNG WILSON WAI-SHUN
                    

•   FOSTER CITY, CA
                      
How do I update this listing?




                                             Cheung Wilson Wai-shun is based out of Foster City.   
                                           














Summary
13D/G
Insider (Form 4)
Hong Kong Holdings



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from CHEUNG WILSON WAI-SHUN, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




cheung wilson wai-shun


SCICLONE PHARMACEUTICALS, INC.

FOSTER CITY
CA
                                                        
                                                    94404









Recent SEC Filings




4 filed on 06/14/2017
4 filed on 03/17/2017
4 filed on 03/09/2017
4 filed on 10/27/2016
4 filed on 10/19/2016
4 filed on 08/29/2016
4 filed on 08/16/2016
4 filed on 03/17/2016
4 filed on 11/10/2015
4 filed on 08/17/2015
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...




**EXPERIMENTAL** Current Hong Kong Exchange Long Positions
Updated daily



Holder
Issuer
Transaction Date
Transaction Type
Avg PPS
Shares Involved
Shares Owned
% Capital
Origin




Cheung Wai Yin Wilson
Merdeka Mobile Group Ltd.
2015-10-12
Long
0.0
100,000,000
496,614,359
40.54%
Hong Kong



Position History



Holder
Issuer
Transaction Date
Transaction Type
Avg PPS
Shares Involved
Shares Owned
% Capital
Origin




Cheung Wai Yin Wilson
Merdeka Mobile Group Ltd.
2015-08-26
Long
0.0
76,000,000
396,614,362
32.37%
Hong Kong


Cheung Wai Yin Wilson
Merdeka Mobile Group Ltd.
2015-08-10
Long
0.0
65,996,875
396,614,361
34.52%
Hong Kong


Cheung Wai Yin Wilson
Merdeka Mobile Group Ltd.
2015-01-28
Long
0.0
330,431,548
330,617,485
86.32%
Hong Kong


Cheung Wai Yin Wilson
Merdeka Mobile Group Ltd.
2014-09-29
Long
0.0
2,314,322,396
330,617,485
86.32%
Hong Kong


Cheung Wai Yin Wilson
Merdeka Mobile Group Ltd.
2014-09-19
Long
0.0
2,353,452,380
2,644,939,880
86.32%
Hong Kong


Cheung Wai Yin Wilson
Merdeka Mobile Group Ltd.
2014-08-15
Long
0.0
10,000,000
291,487,500
9.51%
Hong Kong


Cheung Wai Yin Wilson
Merdeka Mobile Group Ltd.
2014-07-23
Long
0.0
211,190,000
301,487,500
9.84%
Hong Kong


Cheung Wai Yin Wilson
Merdeka Resources Holdings Ltd.
2014-02-27
Long
0.0
0
90,297,500
14.73%
Hong Kong


Cheung Wai Yin Wilson
Merdeka Resources Holdings Ltd.
2014-01-29
Long
0.0
0
90,297,500
16.86%
Hong Kong











Elevate your investments
Try it for free




















SciClone Pharmaceuticals Inc (SCLN.O)  People | Reuters.com


























































X



Edition:

United States


















Africa
América Latina


عربي
Argentina


Brasil
Canada


中国
Deutschland


España
France


India
Italia


日本
México


РОССИЯ
United Kingdom

United States
















SciClone Pharmaceuticals Inc (SCLN.O)










Related Topics: 
StocksStock ScreenerMarket DataHealthcarePharmaceuticals












                
                        Overview
                    



                
                        News
                    



                
                        Key Developments
                    



                
                        People
                    



                
                        Charts
                    



                
                        Financials
                    



                
                        Analysts
                    



                    
                            Research
                        



                    
                            Pulse
                        










				SCLN.O on Nasdaq


				11.00USD
21 Jul 2017





				    Change	(% chg)


		    
						    $0.10


					            (+0.92%)
					        






Prev Close

$10.90


Open

$10.93




Day's High

$11.00


Day's Low

$10.90




Volume

675,399


Avg. Vol

540,020




52-wk High

$11.10


52-wk Low

$8.55











					Summary





Name
Age
Since
Current Position




							Jon Saxe

79
2009

                                Independent Chairman of the Board




							Friedhelm Blobel

66
2013

                                President, Chief Executive Officer, Director




							Wilson Cheung

46
2013

                                Chief Financial Officer, Senior Vice President - Finance, Secretary




							Hong Zhao

51
2013

                                Chief Executive Officer - China Operations




							Raymond Low

58
2013

                                Vice President - Finance, Controller




							Lan Xie

42
2012

                                Vice President - Finance, China Chief Financial Officer




							Nancy Chang

65
2013

                                Independent Director




							Richard Hawkins

67
2004

                                Independent Director




							Anthony Lapointe

57
2009

                                Independent Director




							Simon Li

65
2013

                                Independent Director



» Insider Trading





					Biographies





Name
Description




							Jon Saxe


					
							Mr. Jon S. Saxe J.D., is an Independent Chairman of the Board of SciClone Pharmaceuticals, Inc., since July 29, 2009. He has served as the Chairman of our Board of Directors since July 2009 and as a Director since August 2000. Mr. Saxe was President of PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) from 1995 to early 1999. From 1993 to 1995, Mr. Saxe was President of Saxe Associates, Inc., consultants to venture capital firms and biotechnology, diagnostic, and pharmaceutical companies. He was the President and CEO of Synergen, Inc., a biotechnology company acquired by Amgen, from 1989 to 1993. Mr. Saxe is former Vice President, Licensing and Corporate Development and Head of Patent Law for Hoffmann-LaRoche Inc., where he worked for almost 30 years. Mr. Saxe received his B.S. Ch.E. from Carnegie-Mellon University, his J.D. from George Washington University School of Law and his LL.M. from New York University School of Law. He serves as a director of other public and private companies, including Durect Corporation and as Chairman of VistaGen Therapeutics, Inc.




							Friedhelm Blobel


					
							Dr. Friedhelm Blobel, Ph.D. is President, Chief Executive Officer, Director of SciClone Pharmaceuticals, Inc. He has served as our President, Chief Executive Officer and as a Director since June 2006. From July 2000 to 2006, Dr. Blobel was President, CEO and a Director of Gryphon Therapeutics, Inc., a South San Francisco based biopharmaceutical company. Prior to joining Gryphon Therapeutics in July 2000, Dr. Blobel spent more than two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group including responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer and General Manager in Tokyo, Japan of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas Pharma, Inc.), Senior Vice President of Research and Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana. Dr. Blobel earned his doctorate degree (“Dr.rer.nat.”; a Ph.D. equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany.




							Wilson Cheung


					
							Mr. Wilson W. Cheung has been appointed as Chief Financial Officer, Senior Vice President - Finance, Secretary of SciClone Pharmaceuticals, Inc. Mr. Cheung joined SciClone in July 2013 and serves as Chief Financial Officer, Senior Vice President, Finance and Secretary. Prior to joining SciClone, from 2009 to 2013, Mr. Cheung served in various positions at Velti plc, a publicly traded global mobile marketing and advertising software-as-a-service provider, including most recently as Chief Compliance Officer, Asia Pacific and previously as Chief Financial Officer. From 2004 to 2009, Mr. Cheung served as Chief Financial Officer of AXT, Inc., a publicly traded manufacturer of high performance semi-conductor substrates. Mr. Cheung holds a B.A. degree in Economics/Business from the University of California, Los Angeles and is a Certified Director of Corporate Governance from UCLA’s Executive Program. He is a California Certified Public Accountant (inactive).




							Hong Zhao


					
							Mr. Hong Zhao has been appointed as Chief Executive Officer - China Operations of Sciclone Pharmaceuticals, Inc., effective April 01, 2013. Mr. Zhao joined SciClone as Chief Executive Officer, China Operations, in April 2013. Prior to SciClone, from 2011 to 2013, Mr. Zhao served as Executive Vice President of Simcere Pharmaceutical Group, a manufacturer and supplier of pharmaceuticals in China, where he was responsible for all business operations and had direct reporting responsibility for medical affairs, market access, marketing and sales operations, training and personnel development. Prior to Simcere, from 1999 to 2011, Mr. Zhao held various positions at Novartis China, a health care products company, including most recently, Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai. Mr. Zhao earned a Bachelor of Medicine degree from Nanjing Medical College and an Executive Masters of Business Administration degree from China European International Business School (CEIBS) in Shanghai.




							Raymond Low


					
							Mr. Raymond A. Low is Vice President - Finance, Controller of Sciclone Pharmaceuticals, Inc. He joined SciClone as Vice President, Finance and Controller in October 2013. Prior to joining SciClone, from 2009 to 2013, Mr. Low served as Chief Financial Officer, and from 2005 to 2009 as Corporate Controller at AXT, Inc., a publicly traded manufacturer of high performance semi-conductor substrates. From 2002 to 2004, Mr. Low was Corporate Controller of Therasense, Inc. (now Abbott Laboratories), a health care products company. Mr. Low is a California certified public accountant and a member of the California Society of CPAs. He is a past member of the Chartered Institute of Management Accountants in the United Kingdom. Mr. Low has an M.B.A. degree from Chadwick University, Alabama, a Bachelor of Accounting Science Honors degree from the University of South Africa, and a Bachelor of Commerce degree from Rhodes University, South Africa.




							Lan Xie


					
							Ms. Lan Xie, CPA, is Vice President Finance, China Chief Financial Officer of SciClone Pharmaceuticals, Inc. Ms. Xie joined SciClone as Vice President Finance, China Chief Financial Officer in August 2012. From 2007 to 2012, Ms. Xie served as Vice President of Finance and Investor Relations at ShangPharma Corporation, a pharmaceutical company. From 2005 to 2007, Ms. Xie served as a senior manager, transaction services, at PricewaterhouseCoopers Zhong Tian LLP in Shanghai and from 2003 to 2005, Ms. Xie served as manager, mergers and acquisitions at Deloitte & Touche in New York. Ms. Xie also served in various finance and accounting positions at Reuters Incorporated and PricewaterhouseCoopers in Boston. She is a Massachusetts certified public accountant and received her M.B.A from INSEAD, Singapore/France.




							Nancy Chang


					
							Dr. Nancy T. Chang, Ph.D. is an Independent Director of SciClone Pharmaceuticals, Inc. She has served as a Director since September 2013. Since 2007, Dr. Chang has served as the President of Apex Enterprises, Inc., an investment management company with a major focus on healthcare investments. From 2007 to 2012, she was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors L.L.C. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine, and before that, she worked at the Roche Institute of Molecular Biology. Dr. Chang received her Doctorate in Biological Chemistry from Harvard University.




							Richard Hawkins


					
							Mr. Richard J. Hawkins is an Independent Director of SciClone Pharmaceuticals, Inc., since October 2004. Mr. Hawkins has served as a Director since October 2004. Since 2011, Mr. Hawkins has been the President and Chief Executive Officer of Lumos Pharma, Inc., a privately-held company. Mr. Hawkins has served as the President and Chief Executive Officer of id2, Inc., a privately-held company since 1992, and as the Chairman and CEO of LabNow, Inc., a privately-held company he founded that develops lab-on-a-chip sensor technology to be used in point-of-care diagnostic testing systems since 2003. From 1994 to 2000, Mr. Hawkins co-founded and served as Director at Corning BioPro, a protein contract manufacturing firm. From 1992 to 2000, Mr. Hawkins co-founded and served as Chairman of Sensus Drug Development, which developed and received regulatory approval for SOMAVERT®, a growth hormone antagonist approved for the treatment of acromegaly and now marketed by Pfizer in both the United States and Europe. In 1982, Mr. Hawkins founded Pharmaco, a clinical research organization (CRO) that in 1991 was merged with the predecessor of PPD-Pharmaco, one of the largest CROs in the world today. Mr. Hawkins has served as a member of the board of directors of Cytori Therapeutics, Inc. since 2007. Mr. Hawkins graduated cum laude with a B.S. in Biology from Ohio University.




							Anthony Lapointe


					
							Mr. Gregg A. Lapointe, CPA, is an Independent Director of SciClone Pharmaceuticals, Inc., since March 2009. Mr. Lapointe has served as a Director since March 2009. Mr. Lapointe is currently the Chief Executive Officer of Cerium Pharmaceuticals, Inc., a specialty pharmaceutical company. From April 2008 to February 2012, Mr. Lapointe served as Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc., a pharmaceutical company focused on rare disorders and the U.S. wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A. He served as Chief Operating Officer of Sigma-Tau Pharmaceuticals, Inc. from December 2003 to March 2008. Mr. Lapointe is a Certified Public Accountant in the United States. He holds a Bachelor of Commerce degree from Concordia University of Montreal, a Graduate Diploma in Public Accountancy from McGill University of Montreal and an M.B.A. from Duke University.




							Simon Li


					
							Mr. Simon Li is an Independent Director of SciClone Pharmaceuticals, Inc., since January 2013. Most recently, Mr. Li has served as a Director since January 2013. He is currently the Chairman and Chief Executive Officer of JW Medical System Ltd., an affiliated company of Biosensors International Ltd. From 2006 to 2012, Mr. Li served in various positions at Medtronic, a global medical technology company, including as the Global Officer and Member of the Executive Committee of Medtronic and President, Greater China and Chairman of the Board, Medtronic-Weigao JV. Prior to Medtronic, from 1999 to 2005, Mr. Li served in various positions at Johnson & Johnson Medical, China (“J&J”) including International Vice President, North Asia/New Business Development, Asia Pacific/Strategic Medical Affairs, Asia Pacific. Earlier in his career with J&J, he held the positions of International Vice President, North Asia, Managing Director, China and Hong Kong, and Managing Director, China. Prior to J&J, Mr. Li was President and Chief Operating Officer of the ConvaTec business with Bristol-Myers Squibb in Hong Kong. He also served as General Manager of the pharmaceutical distributor Y.C. Woo & Co., Ltd. in Hong Kong. He earned a Bachelor of Arts degree in social sciences from the University of Hong Kong, an M.B.A. degree from Henley Management, and an advanced E.M.B.A. from Harvard Business School.











					Basic Compensation





Name
Fiscal Year Total




							Jon Saxe

--




							Friedhelm Blobel

1,514,780




							Wilson Cheung

726,368




							Hong Zhao

993,010




							Raymond Low

--




							Lan Xie

509,461




							Nancy Chang

--




							Richard Hawkins

--




							Anthony Lapointe

--




							Simon Li

--



As Of 
30 Dec 2014





					Options Compensation





Name
Options
Value




							Jon Saxe

0
0




							Friedhelm Blobel

0
0




							Wilson Cheung

0
0




							Hong Zhao

0
0




							Raymond Low

0
0




							Lan Xie

0
0




							Nancy Chang

0
0




							Richard Hawkins

0
0




							Anthony Lapointe

0
0




							Simon Li

0
0









					Insider Trading












Name
Shares Traded
Price


Blobel (Friedhelm)
7,390
$5.13


Blobel (Friedhelm)
27,654
$11.00


Blobel (Friedhelm)
27,654
$3.55


Blobel (Friedhelm)
7,390
$11.00


Blobel (Friedhelm)
30,000
$10.90


Blobel (Friedhelm)
30,000
$3.55


Blobel (Friedhelm)
40,000
$10.91


Blobel (Friedhelm)
40,000
$3.55


Xie Lan
1,000
$0.00


Cheung (Wilson Wai Shun)
3,000
$10.75


Blobel (Friedhelm)
26,090
$10.75


Zhao Hong
3,000
$0.00


Zhao Hong
12,500
$0.00


Cheung (Wilson Wai Shun)
25,000
$10.75


Blobel (Friedhelm)
5,000
$0.00


Zhao Hong
12,500
$10.75


Low (Raymond Anthony CPA)
1,250
$0.00


Xie Lan
1,000
$10.75


Cheung (Wilson Wai Shun)
12,500
$0.00


Cheung (Wilson Wai Shun)
3,000
$0.00


Cheung (Wilson Wai Shun)
12,500
$10.75


Zhao Hong
25,000
$0.00


Zhao Hong
25,000
$10.75


Blobel (Friedhelm)
50,000
$0.00


Zhao Hong
3,000
$10.75




» Full list on Insider Trading
















Related Topics: 
StocksStock ScreenerMarket DataHealthcarePharmaceuticals




















